CD8A and diffuse large B-cell lymphoma: Moreover, the model showed potential to predict baseline response to chimeric antigen receptor T-cell (CAR-T) therapy.<h4>Conclusion</h4>This study highlights CD8+ T cell heterogeneity in DLBCL and establishes a prognostic gene signature that informs patient survival prediction and CAR-T therapy efficacy.